Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

Stephanie, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Stephanie's Patient Story

Patient Info: Stephanie, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: ovaries; spine; liver; lung

Stage IV ALK-positive NSCLC is being managed with ALK-directed treatment; follow-up scans were described as improving, but the source does not state complete remission.

The Patient Story
OutcomeResponding Well
Jennifer, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IV Small Cell Lung Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Robertson, Female, 40s | Stage IV

Metastatic Site: Collar bones; shoulder blades; femur; pancreas;…

As of February 2026, Jennifer had shown no evidence of disease since August 2025 after tarlatamab-dlle and whole-brain radiation, while continuing tarlatamab infusions every other Monday and scans every 3 months.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR L858R lung adenocarcinoma with rapid neurologic decline

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR L858R mutation; CK7-positive; Napsin A-positive; TTF-1-positive; p40-negative; Ki-67 about 1%

Metastatic Site: brain parenchyma and meninges

The patient developed rapidly progressive cognitive decline with multifocal brain lesions. Lung biopsy confirmed EGFR L858R lung adenocarcinoma, and she received amivantamab, but neurologic deterioration continued and she died in the fourth month of the disease course.

PubMed Central
OutcomeIn Memory
Ruchira, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Ruchira's Survivor Story

Patient Info: Ruchira, Female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Not reported

Although the disease progressed to Stage IV after lobectomy, ALK testing led to lorlatinib; she reported no evidence of disease after 3 months and continued daily targeted therapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

BRAF-mutant stage IV lung adenocarcinoma complicated by immunotherapy-induced diabetes

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: BRAF mutation; GADA-positive during immune-related diabetes evaluation

Metastatic Site: left lower lung, pleural

The patient had Stage IV BRAF V600E-mutant lung adenocarcinoma treated with targeted therapy and later tislelizumab. Immunotherapy was suspended after hypoadrenocorticism and diabetic ketosis; she required ongoing insulin therapy, with persistently low C-peptide at 6-month follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage 4 lung cancer: large tumor managed with targeted care

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS <1%

Metastatic Site: contralateral lymph nodes, supraclavicular lymph…

The patient had a partial response to CheckMate 9LA despite PD-L1 TPS <1%, later progressed after 24 cycles of immunotherapy, received additional chemotherapy, and died in November 20XX+2.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: never-smoker with complete remission

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR20ins mutation; TP53 p.Q192 mutation; PD-L1 TPS 0%; CPS 0%

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bilateral…

The patient had a durable response to high-dose furmonertinib, later developed a right cerebellar metastasis treated with stereotactic radiation, and continued to benefit from furmonertinib as of April 2025 with 27 months of progression-free survival reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Kidney damage as a rare side effect of durvalumab immunotherapy

Patient Info: Anonymized, Male, 70+

The lung-cancer burden decreased during treatment. Durvalumab was stopped because of nephrotic syndrome, which achieved sustained complete remission with prednisolone.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

EGFR R252C multifocal lung cancer responding to afatinib

Patient Info: Anonymized

Biomarkers: EGFR R252C extracellular-domain mutation

Afatinib was associated with suppression of primary tumor growth and extended progression-free survival in a patient with multifocal lung cancer and glioma driven by EGFR R252C. Stage and metastatic sites were not established from the available case summary.

PubMed Central
OutcomeResponding Well
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer treatment and follow-up story

Patient Info: Tina Powell, Female | Stage IV

As of January 2026, Tina was 3 years into Stage IV lung cancer, on a clinical trial at Memorial Sloan Kettering, and undergoing CT chest, CT pelvis, and brain MRI every 6 weeks.

YouTube (JA search)
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: persistent cough led to diagnosis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS and TP53 ; PD-L1 TPS 95%. Other common lung drivers were not detected.

Metastatic Site: liver, left adrenal gland, lymph nodes, pleural…

After more than 2 years of disease control and partial response on antiangiogenic therapy plus sintilimab, the patient developed fulminant immune-checkpoint-inhibitor-induced type 1 diabetes with severe diabetic ketoacidosis, inflammatory crisis, sepsis, and died shortly after discharge against medical advice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lynch-associated lung and colorectal cancers responded to immunotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: dMMR/MSI-H pattern with MLH1/PMS2 loss and germline MLH1 mutation; KRAS and PTEN mutations; PD-L1 TPS 15%.

Metastatic Site: right paraspinal metastatic lesion from lung…

After starting iparomlimab plus tuvonralimab, pleural and pelvic disease improved, intestinal wall involvement decreased further after 5 cycles, the paraspinal lung metastasis remained stable, tumor markers stayed normal, and treatment continued.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV non-small cell lung cancer: treatment and follow-up story

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: ALK mutation/rearrangement; EGFR negative

Metastatic Site: Bone, including left humerus

As of January 2026, he described about 3 years on ALK-targeted oral therapy, feeling well, exercising 3-4 times per week, and living close to normal life with Stage IV ALK-positive lung cancer.

YouTube (ZH search)
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

Pulmonary splenosis mimicked lung cancer after prior splenectomy

Patient Info: Anonymized, Male, 60s

Biomarkers: No lung cancer confirmed. Biopsy showed splenic tissue; lung tumor markers were normal.

The suspected left lower-lobe lung mass was confirmed by biopsy to be splenic tissue rather than cancer, and follow-up showed the mass remained unchanged compared with prior imaging.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

MET exon 14 skipping lung adenocarcinoma: sequential MET-TKI toxicity and ongoing chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; EGFR negative; ALK negative; ROS1 negative; PD-L1 tumor proportion score 10%

Metastatic Site: pleura

The cancer recurred with pleural dissemination after surgery and adjuvant UFT. Sequential MET inhibitors and systemic therapies provided periods of disease control but were limited by ILD and non-ILD toxicities; at the report, he remained on carboplatin, pemetrexed, and bevacizumab.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage IA primary mucinous lung adenocarcinoma with enteric differentiation in a patient with CLL/SLL

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: Lung tumor markers supported mucinous adenocarcinoma with enteric features. CLL/SLL markers were present in lymph nodes, not lung metastasis.

As of January 2026, he remained free of lung cancer for 24 months after thoracoscopic wedge resection of localized Stage IA primary mucinous lung adenocarcinoma, while CLL/SLL continued to be managed separately.

PubMed Central
OutcomeCancer-Free / NED